Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться

Sanofi

Специалисты компании

Личные визитки людей, которые сами указали это место работы и разрешили показ здесь. Имена из реестров мы не берём.

Пока никто не показал здесь свою визитку.

Работаете здесь? Покажите свою визитку: фото, должность, кнопка «Написать». Почту и телефон не показываем. Только с вашего разрешения, убрать можно в любой момент. Я здесь работаю — показать мою визитку

Нашли ошибку или чужую визитку? Сообщить модератору

2
исследования идут сейчас
123
исследования в базе
112
Россия · идут 2
8
Беларусь
3
Казахстан

Разрешения по годам

Новые препаратыБиоэквивалентность

Фазы

Фаза II 15
Фаза II–III 6
Фаза III 86
Фаза IV 11

Области

Пока нет данных

Завершено Фаза III Россия
Lixisenatide (AVE0010); Exenatide; Metformin · Sanofi

A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin

639 участников во всех странах ClinicalTrials.gov EFC6019
Прекращено Фаза III Россия
Semuloparin sodium; Enoxaparin sodium · Sanofi

A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

421 участник во всех странах ClinicalTrials.gov EFC10572
Завершено Фаза III Россия
Lixisenatide (AVE0010); Placebo; Insulin glargine; Metformin; Thiazolidinedione (TZD) · Sanofi

A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin

446 участников во всех странах ClinicalTrials.gov EFC10781
Завершено Фаза II Россия
SSR150106; Placebos · Sanofi

Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis (RA): A 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of 90 µg Administered Once Daily and 90 µg Once Every Other Day

79 участников во всех странах ClinicalTrials.gov ACT5488
Завершено Фаза III Россия
Semuloparin Sodium; Enoxaparin sodium; Placebo · Sanofi

A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

4 413 участников во всех странах ClinicalTrials.gov EFC6520
Завершено Фаза III Россия
dronedarone (SR33589); amiodarone · Sanofi

Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation (AF)

504 участника во всех странах ClinicalTrials.gov EFC4968
Завершено Фаза II Россия
aflibercept; oxaliplatin; 5-FU; Folinic Acid · Sanofi

Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

268 участников во всех странах ClinicalTrials.gov EFC10668
Завершено Фаза III Россия
amibegron (SR58611A) · Sanofi

A Fifty-Two-Week Multicenter, Open-Label, Study Evaluating the Long-Term Safety and Tolerability of SR58611A 350 mg q12 in Patients With Major Depressive Disorder.

527 участников во всех странах ClinicalTrials.gov LTS4848
Завершено Фаза III Россия
Fexofenadine · Sanofi

A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma

1 000 участников во всех странах ClinicalTrials.gov M016455P/3001
Завершено Фаза III Россия
SR121463B · Sanofi

An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

57 участников во всех странах ClinicalTrials.gov SFY5904
Завершено Фаза III Россия
Larotaxel (XRP9881); 5-Fluorouracil; Capecitabine · Sanofi

A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen

408 участников во всех странах ClinicalTrials.gov EFC6596
Завершено Фаза III Россия
dronedarone (SR33589); placebo · Sanofi

A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)

4 628 участников во всех странах ClinicalTrials.gov EFC5555
Завершено Фаза III Россия
volinanserin; placebo · Sanofi

Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study

604 участника во всех странах ClinicalTrials.gov EFC6072
Завершено Фаза III Россия
saredutant (SR48968); placebo; escitalopram · Sanofi

An Eight-week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients With Major Depressive Disorder

393 участника во всех странах ClinicalTrials.gov EFC5574
Завершено Фаза III Россия
Ciclesonide (XRP1526) · Sanofi

A Multinational,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered Either in a Once-Daily in the Morning Regimen (160 μg qd AM) for 16 Weeks or in a 160 μg qd AM Regimen for 12 Weeks Preceded by a Twice-Daily Regimen (80 μg Bid) for 4 Weeks,or in an 80 μg Bid Regimen for 16 Weeks,in Adults and Adolescents With Mild to Moderate Persistent Asthma Not Treated With Steroids

708 участников во всех странах ClinicalTrials.gov EFC6164
Завершено Фаза III Россия
volinanserin (M100907); Placebo · Sanofi

Efficacy and Safety of 2 mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study

848 участников во всех странах ClinicalTrials.gov LTE6672
Завершено Фаза IV Россия
Insulin Glargine · Sanofi

Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus

555 участников во всех странах ClinicalTrials.gov LANTU_R_04889
Завершено Фаза III Россия
Alfuzosin · Sanofi

12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension

25 участников во всех странах ClinicalTrials.gov EFC6269

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.